Taro Pharma (TARO) Misses Q2 EPS by 26c, Revenues Miss; Announces $300M Share Buyback
Tweet Send to a Friend
Taro Pharma (NYSE: TARO) reported Q2 EPS of $1.46, $0.26 worse than the analyst estimate of $1.72. Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
